A Phase Ia Study in Patients with Advanced Solid Tumors for the Human Monoclonal Antibody Vantictumab (OMP-18R5; Anti-Frizzled)

A Phase Ia Study in Patients with Advanced Solid Tumors for the Human Monoclonal Antibody Vantictumab (OMP-18R5; Anti-Frizzled)

A Phase Ia study in patients with advanced solid tumors for the human 890 monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway Kyriakos Papadopoulos,1 Lee Rosen,2 Rashmi Chugh,3 Jonathan Goldman,2 Wan-Ching Yen,4 Pete Yeung,4 Lu Xu,4 Ann M. Kapoun,4 Rainer K. Brachmann,4 Robert Stagg,4 Tony Tolcher,1 David Smith3 1START, San Antonio, TX, USA; 2Univervisity of California, Los Angeles, CA, USA; 3University of Michigan, Ann Arbor, MI, USA; 4OncoMed Pharmaceuticals, Redwood City, CA, USA BACKGROUND STUDY OVERVIEW SAFETY PHARMACODYNAMICS TIME ON STUDY • Failure to effectively target Cancer Stem Cells (CSCs) may • Patients with advanced solid tumors Vantictumab affects Wnt-related gene expression 029 Vertical lines: tumor assessments Related adverse events observed in >5% of patients 028 be responsible for the limited success of systemic therapies patterns in hair follicles 027 Unrelated serious adverse event • 3+3 dose escalation 026 in the metastatic setting. 025 Unrelated serious adverse event • Dose levels 1 2 3 4 5 6 7 8 Total 024 Cohort • The activated Wnt pathway is strongly associated with (n=3) (n=5) (n=3) (n=4) (n=3) (n=3) (n=3) (n=1) (n=25) 023 • 0.5 and 1 mg/kg every one week 022 CSCs. 0.5 1 0.5 1 2.5 5 10 15 021 Dose level • 0.5 mg/kg every two weeks q1wk q1wk q2wk q3wk q3wk q3wk q3wk q3wk 020 Investigator decision (lack of clinical benefit) • Vantictumab is a fully human IgG monoclonal antibody that 019 Investigator decision (changes in patient’s condition, further treatment unacceptable) 2 018 Grade 1/2/3 1/2/3 1/2/3 1/2/3 1/2/3 1/2/3 1/2/3 1/2/3 was identified by binding to Frizzled 7. • 1, 2.5, 5, 10 and 15 mg/kg every three weeks Control 017 subjects 016 • DLT assessment window: 28 days Fatigue 015 • Vantictumab binds five Frizzled receptors (1, 2, 5, 7, and 8) -/1/- -/1/- 3/-/- -/-/- -/-/- -/1/- 1/-/- -/-/- 7 (28%) 014 and inhibits Wnt signaling. 013 • Pharmacodynamics: blood RNA, hair follicles, tumor Nausea -/-/- -/1/- 2/-/- -/-/- 1/-/- 1/-/- -/-/- -/-/- 5 (20%) 012 • Vantictumab has broad anti-tumor activity in patient-derived (optional) 011 Decreased 010 xenograft models, in particular when combined with -/-/- -/1/- -/-/- 1/-/- -/-/- -/1/- 1/-/- -/-/- 4 (16%) 009 • Tumor assessments: every 8 weeks appetite 008 standard-of-care chemotherapy, such as taxanes. 007 = Active Hypercalcemia -/-/- -/-/- -/-/- -/-/- 1/-/- -/2/- 1/-/- -/-/- 4 (16%) 006 • Vantictumab selectively reduces the frequency of CSCs in 005 004 Dose-limiting toxicity = Neuroendocrine tumor these models. Vomiting 1/-/- 1/-/1* -/-/- -/-/- 1/-/- -/-/- -/-/- -/-/- 4 (16%) 003 BASELINE CHARACTERISTICS 002 001 • Vantictumab can also promote widespread tumor cell Constipation -/-/- -/-/- 1/-/- 1/-/- -/-/- -/-/- 1/-/- -/-/- 3 (12%) differentiation, as shown for pancreatic cancer models. 0 56 112 168 224 280 336 392 448 504 Abdominal pain 1/-/- -/-/- 1/-/- -/-/- -/-/- -/-/- -/-/- -/-/- 2 (8%) Days on study For more details, see Gurney et al., PNAS 109, 11717 (2012). Number of patients 25 Alkaline phos- -/-/- 2/-/- -/-/- -/-/- -/-/- -/-/- -/-/- -/-/- 2 (8%) Data as of 10 September 2013; patients discontinued vantictumab for progressive Median age, yr (range) 59 (38-77) phatase increased disease unless another reason is shown. Gender (female) 15 (64%) Anemia -/-/- -/1/- -/-/- -/1/- -/-/- -/-/- -/-/- -/-/- 2 (8%) • Vantictumab causes decreased expression of Wnt pathway NONCLINICAL EFFICACY DATA target genes and increased expression of differentiation ECOG score Diarrhea 1/-/- -/-/1* -/-/- -/-/- -/-/- -/-/- -/-/- -/-/- 2 (8%) Three neuroendocrine tumor patients genes (‘OMP18R5;’ in red). with prolonged stable disease Dose-ranging experiment 0 6 (24%) • Hair follicles of control subjects not treated with Data as of 2 August 2013 in patient-derived breast cancer xenograft 1 19 (76%) vantictumab show no significant changes in the same 003 (59 yo female) 010 (69 yo female) 012 (77 yo female) q1wk = every 1 week; q2wk = every 2 weeks; q3wk = every 3 weeks genes (‘Ctrl;’ in gray). Carcinoid Pancreatic neuroendocrine Carcinoid 1500 tumor Number of prior systemic * Grade 3 vomiting and diarrhea of patient 004 were the only Grade ≥3 adverse Diagnosis: Diagnosis: 3 paclitaxel 3 (1-8) • 10 patient samples analyzed: 9 collected 1 week after Diagnosis: 1200 therapies, median (range) events and were considered dose-limiting toxicities for Cohort 2. 2004: resection (curative 2006: liver mets vantictumab (5 mg/kg) + paclitaxel infusion; 1 collected 2 weeks after infusion vantictumab (10 mg/kg) + paclitaxel intent) 2001: resection (curative 900 Systemic Therapy: vantictumab (25 mg/kg) + paclitaxel Tumor types intent) Systemic Therapy: 1. Sandostatin (569 vantictumab (45 mg/kg) + paclitaxel 2006: liver mets 600 1. MEK inhibitor + AKT days) Colon 8 Systemic Therapy: 300 BONE TURNOVER inhibitor (55 days) 2. HSP90 inhibitor (710 Tumor Volume, mm Neuroendocrine 4 • PD confirmed 1. Regorafenib (1093 days) 0 days) 0 20 40 60 80 (+26%) 3. αAng2 (336 days) Days Post Treatment vantictumab: q3wk Breast 2 2. Vantictumab (110 days) 2. αLOXL2 (168 days) paclitaxel: 10 mg/kg, q1wk • Patient 003 experienced Grade 2 compression fracture after minor • PD confirmed fall on Day 110. 3. αCSFR1 (42 days) (+20%) Sarcoma 2 • PD confirmed (+45%) Established UM-PE13 tumors (triple-negative breast) were treated • Review of program for bone toxicity resulted in revised safety plan. 4. Vantictumab (SD; with various doses of vantictumab (OMP-18R5) in combination with Other 9 4. Vantictumab (448 days) 441+ days) paclitaxel. 5 mg/kg every 3 weeks (q3wk) of vantictumab resulted in • More stringent exclusion criteria Data as of 2 August 2013 a reduction relative to paclitaxel alone and established the minimum (e.g. chronic glucocorticoid use, high β C-terminal telopeptide efficacious dose. Treatment at 25 mg/kg q3wk resulted in tumor [β -CTX, serum marker of bone turnover], and known regression and corresponds to the maximum efficacious dose. insufficiency fracture) CONCLUSIONS PHARMACOKINETICS • Prophylactic Vitamin D and calcium supplements Dose-partitioning experiment in patient-derived breast • Less frequent dosing • Vantictumab is well tolerated. cancer xenograft to determine PK driver of efficacy • Zoledronic acid for the following criteria • Further dose escalation is ongoing. • Doubling of β-CTX, serum marker for bone turnover • Vantictumab clearance is dose-dependent, • T-score decline to <-2.5 as measured by DEXA scan consistent with target-mediated disposition. T- T- T- T- • A statistically significant correlation was • Vantictumab has pharmacodynamic (PD) effects Ranking of PK parameters Dose Pt Day ß-Ctx Dose Pt Day ß-Ctx Dose Pt Day ß-Ctx Dose Pt Day ß-Ctx at Steady State: (mg/kg) (pg/ml) score (mg/kg) (pg/ml) score (mg/kg) (pg/ml) score (mg/kg) (pg/ml) score observed between β-CTX increases and the on hair follicles. 1 0 570 -1.8 0 689 -1.4 0 386 -0.7 Term -2.2 0 927 -0.7 fraction of time that the serum concentration ¾ AUC: 1x q1w = 2x q2w = 3x q3w = 4x q4w 25 0.5 0 196 -1.0 1 28 846 2.5 16 28 805 15 28 ND • PD effects are consistent with Wnt biology. ¾ Cmax: 4x q4w > 3x q3w > 2x q2w > 1x q1w 2 28 308 of vantictumab was above a threshold of 2 q1w Term 217 ND q3w 56 707 -1.3 q3w Term 345 -0.8 q3w 0 596 -1.3 ¾ Cmin: 1x q1w > 2x q2w > 3x q3w > 4x q4w 0 219 -0.1 84 350 0 232 -1 26 28 1171 µg/mL. 28 825 17 • PD effects extend beyond serum exposure. 3 56 896 112 759 -1.4 28 309 56 1278 -1.5 Term 708 0.2 140 526 0 607 -0.9 0 492 -1.9 •Cmax or AUC did not correlate with β-CTX • Target efficacious dose was reached at dose level 4 0 298 -1.3 27 Term 401 ND 168 967 -1.8 18 28 555 28 ND increases. 1400 1 0 229 -1.2 196 688 Term 824 -1.0 0 385 +0.6 of 10 mg/kg every three weeks. 5 28 681 12 28 ) Control q1w 224 1216 -1.7 3 1200 Term 370 -1.0 0 648 0.1 28 667 • These findings suggest: paclitaxel 6 0 162 -0.4 252 1174 5 19 28 811 •Cmax is PK driver of efficacy in nonclinical 1000 28 598 29 0 964 NID •C may be the driver for β-CTX vantictumab (10mg/kg q1wk) + paclitaxel 0 144 0.9 280 1223 -1.7 q3w Term 1336 -0.1 min 800 vantictumab (20mg/kg q2wk) + paclitaxel 7 28 301 308 1045 efficacy models. Term 0.7 0 561 -1.0 increases. 600 vantictumab (30mg/kg q3wk) + paclitaxel 0 406 -1.6 336 890 -1.9 Active patients 8 20 28 665 vantictumab (40mg/kg q4wk) + paclitaxel 28 551 364 1380* • High intermittent dosing that allows drug • Vantictumab has PD effects on bone, as 400 0 203 -0.7 56 1111 -1.0 9 28 195 392 1332 NID Zoledronic acid Term 287 -0.9 washout below a threshold may evidenced by β-CTX increases. tumor volume (mm volume tumor 200 0.5 21 0 629 -0.13 administered 0 306 -1.4 420 218 0 q2w 28 286 ameliorate bone toxicity. 0 618 -0.9 0 367 -1.2 Red bold: •C (or time above a certain threshold) 0 10 20 30 40 50 60 56 304 -1.0 13 22 min 84 664 Term 876 -1.2 10 28 697 β-CTX doubling by Day 28 Days Post Treatment 112 270 -0.9 0 471 2.4 appears to be the PK driver of toxicity. 140 288 q3w 0 568 -1.3 14 28 760 168 413 -1.0 23 28 1449 Green bold: At current dose levels: 196 372 Term 688 2.2 • Increased bone turnover can be safely managed The top graph shows the PK parameters associated with the various 224 377 -0.9 Term 199 -1.6 β-CTX doubling > Day 28 10 252 363 0 340 -0.7 doses and schedules of vanticumab.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    1 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us